Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Abstract Text:

Min Li,Uddalak Bharadwaj,Rongxin Zhang,Sheng Zhang,Hong Mu,William E Fisher,F Charles Brunicardi,Changyi Chen,Qizhi Yao,

Given the high fatality rate of pancreatic cancer, an effective treatment for this devastating disease is urgently needed. We have shown that mesothelin expression was higher in human pancreatic cancer cells than in human pancreatic duct epithelial cells, and mesothelin mRNA was substantially overexpressed in 18 of 21 (86%) clinical pancreatic adenocarcinoma specimens when compared with the surrounding normal tissues. However, the biological functions of mesothelin in tumor progression are not clearly understood. Here we studied the effects of mesothelin overexpression in pancreatic cancer cell proliferation and migration in vitro and pancreatic cancer progression in vivo. We found that forced expression of mesothelin significantly increased tumor cell proliferation and migration by 90% and 300%, respectively, and increased tumor volume by 4-fold in the nude mice xenograft model when compared with the vector control cell line. Silencing of mesothelin inhibited cell proliferation and migration in pancreatic cancer cells and ablated tumor progression in vivo. Vaccination with chimeric virus-like particles that contain human mesothelin substantially inhibited tumor progression in C57BL/6J mice. The increases in mesothelin-specific antibodies and CTL activity and the decrease in regulatory T cells correlated with reduced tumor progression and prolonged survival. This study revealed novel functions of mesothelin and suggested a new therapeutic vaccine strategy whereby mesothelin is targeted to control pancreatic cancer progression. [Mol Cancer Ther 2008;7(2):286-96].

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Publishing Authors By Initials

M Li,U Bharadwaj,R Zhang,S Zhang,H Mu,WE Fisher,FC Brunicardi,C Chen,Q Yao,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Molecular cancer therapeutics

VOLUME: 7

Page Numbers: 286-96

Journal Abbreviation: Mol. Cancer Ther.

ISSN: 1535-7163

DAY: 18

MONTH: Feb

YEAR: 2008

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101132535

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

AFFILIATION: Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Mail stop: NAB-2010, Houston, TX 77030. qizhiyao@bcm.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Related Publications

• Regulation of secretion of osteoprotegerin in rat dental follicle cells.
• [A case of hemorrhagic fever with renal syndrome]
• [A dual-color fluorescence in situ hybridization study on the detection of inv(16) in acute myeloid leukemia]
• [Applying exponent method of density to amend bone's edge of X-ray image]
• [Clinical study of plasma substitute (Gelofusion) on fluid resuscitation in patients with burned shock]
• [Determination of aluminium in healthman hair by FAAS and FAES]
• [Determination of trace elements in shenrong heixi wan]
• [Development and application of an indirect immunofluorescence assay for the detection of serum immunoglobulin G to human herpesvirus 6]
• [Effectiveness of caring on chronic cases of filariasis in Zhejiang Province]
• [Effects of anticoagulation therapy with low molecular weight heparin in acute pancreatitis.]
• [Effects of esmolol and fentanyl on the hemodynamic and catecholamine response to tracheal intubation in hypertensive patients]
• [Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia]
• [Experimental study on viscoelasticity of spinal lumbar vertebrae (T12-S1) by simulating the operation of excising intervertebral disc and planting bone on back route and the operation of excising intervertebral disc and inserting fusion cage]
• [Induction of apoptosis of HepG2 cells by NDRG2]
• [Pathological changes between HBeAg and anti-HBe in patients with chronic hepatitis B]
• [Progress of surface enhanced Raman spectroscopic studies in nonaqueous systems]
• [Propofol reduces intercellular adhesion molecular-1 expression in lung injury following intestinal ischemia/reperfusion in rats.]
• [Report of a survived neonate born to the mother who had liver transplantation]
• [Retrocaval ureter]
• [Specific humoral immuneresponse in Rhesus monkeys vaccinated immune response with Abeta42 peptide vaccine]
• [Stress on clinical research of primary biliary cirrhosis]
• [Study on laser flash spectroscopy of laser-induced interaction of DNA and polynucleotides with SO4*-]
• [Study on the action force of dimerization of cobalt tetrasulfonate Ph-thalocyanine in aqueous solotion]
• [The detection of serum hepatitis B virus Pre-S1 antigen and its relationship with HBeAg/anti-HBe and HBV DNA by polymerase chain reaction]
• [The diagnosis and treatment of acute necrotizing fascitis in 14 patients]
• [The expression of CXCR4 on acute leukemia cells and its implication for extramedullary infiltration]
• [The implementation of sharing treatment planning system based on DICOM]
• [The progress in inhibitors of Janus kinases/signal transducers and activators of transcription pathway]
• [The recent development of genomic polymorphism in sepsis]
• [X-ray microanalysis of the activity of immobilized L-asparaginase]